Market Overview:

The global COVID-19 diagnostics market size reached US$ 94.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 32.1 Billion by 2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

COVID-19 diagnostics refer to the clinical tests conducted to detect the presence of the viral infection among individuals. COVID-19 is an infectious disease caused by the newly discovered zoonotic coronavirus. Some common symptoms include fever, fatigue, dry cough, shortness of breath, sore throat and body aches. The viral infection is usually diagnosed through reverse transcriptase-polymerase chain reaction (RT- PCR), antigen-based and antibody testing. These tests use reagents and kits to obtain the sample from nasopharyngeal (NP), oropharyngeal (OP) and nasal swabs, human saliva or blood. They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.

The sudden outbreak of coronavirus disease and an alarming increase in the number of COVID-19 cases across the globe are among the key factors creating a positive outlook for the market growth. The continuous rise in the number of daily cases has led to the widespread adoption of diagnostic tests for rapid and comprehensive testing to provide early treatment to the patients. In line with this, the increasing demand for mass testing and molecular diagnostics is contributing to the market growth. Additionally, various product innovations, such as the launch of novel antibody and serology test kits for home-testing, are acting as other growth-inducing factors. In comparison to the traditionally used testing kits, these variants are less time-consuming and can be integrated with software-based programs for accurate results. Other factors, including the implementation of favorable government polices to prevent the further spread of COVID-19 infection, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global COVID-19 diagnostics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, sample type, test type, mode and end use.

Breakup by Product Type:

• Reagents and Kits
• Instruments
• Others
   

Breakup by Sample Type:

• Nasopharyngeal Swabs
• Oropharyngeal Swabs
• Nasal Swabs
• Blood
• Others
   

Breakup by Test Type:

• Molecular (RT-PCR) Testing
• Antigen-based Testing
• Antibody (Serology) Testing
• Others
   

Breakup by Mode:

• Point-of-Care (PoC)
• Non-Point-of-Care (Non-PoC)
   

Breakup by End Use:

• Laboratories
• Hospitals
• Diagnostic Centers and Clinics
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft and Thermo Fisher Scientific Inc.

Report Coverage: